Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705185 · ClinicalTrials.gov registry record
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 120
- Enrollment target
NCT00705185: Completed study, sponsored by Massachusetts General Hospital.
NCT00705185 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00705185 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers. Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to study NCT00555997) and compare these results to those of healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-06 |
What the finished NCT00705185 record still lists
NCT00705185 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00705185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00705185 about?
NCT00705185 is a clinical study titled "Exploring a Potential Blood Test to Diagnose Major Depressive Disorder". The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers. Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to st...
What is the current status of trial NCT00705185?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2008-04. Estimated completion is 2010-06.
Who is sponsoring clinical trial NCT00705185?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia